Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 1

Status

Completed 13Terminated 7Recruiting 5Active not recruiting 4Withdrawn 2Unknown 2Suspended 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Dermatologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 117Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 55Melanoma 54Lung Neoplasms 49Neoplasm Metastasis 47Breast Neoplasms 42Neoplasms 38Colorectal Neoplasms 37Head and Neck Neoplasms 26Endometrial Neoplasms 25Carcinoma, Renal Cell 25Ovarian Neoplasms 22Uterine Cervical Neoplasms 21Stomach Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Recurrence 16Esophageal Neoplasms 16Pancreatic Neoplasms 15Carcinoma, Hepatocellular 14Sarcoma 12Glioblastoma 12Carcinoma, Squamous Cell 12Prostatic Neoplasms 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

Cyclophosphamide 28fludarabine 19Rituximab 17obinutuzumab 12venetoclax 10Lenalidomide 9Bendamustine Hydrochloride 9Prednisone 7zanubrutinib 6Doxorubicin 6Blood Specimen Collection 6pembrolizumab 5ibrutinib 5fludarabine phosphate 5Biopsy 5glofitamab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Exercise 4loncastuximab tesirine 3gamma-Globulins 3axicabtagene ciloleucel 3acalabrutinib 3Temozolomide 3Surveys and Questionnaires 3Palliative Care 3Mycophenolic Acid 3Methotrexate 3Mesna 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Lymphoma × pembrolizumab × Clear all
NCT07302347 2026-05-26

MK-3475-G21

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
20 enrolled
DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT06137144 2026-05-19

PRIMAVERA

AstraZeneca

Phase 1/2 Recruiting
161 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT02332668 2026-05-18

MK-3475-051

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
370 enrolled
DermatologicLymphoid

Lymphoma, Melanoma

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Dana-Farber Cancer Institute

Phase 1 Recruiting
15 enrolled
Lymphoid

Lymphoma

NCT03829254 2026-01-12

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

NuCana plc

Phase 1/2 Recruiting
135 enrolled
DermatologicLymphoid

Lymphoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡